EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lipoprotein(a) in clinical practice: A guide for the clinician

Chayakrit Krittanawong, Neil Sagar Maitra, Adham H El-Sherbini, Nishant Shah, Carl J Lavie, Michael D Shapiro, Salim S Virani

Progress in Cardiovascular Diseases · 2023

DOI: 10.1016/j.pcad.2023.07.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2023. Verfasst von Chayakrit Krittanawong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, NYU Langone Health and NYU School of Medicine, New York, NY, United States of America. Electronic address: chayakrit.krittanawon…. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Cardiovascular Diseases, Atherosclerosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disease (CVD) remains the leading cause of death worldwide. Serum lipoprotein(a) (Lp(a)) has been shown to be an independent and causative risk factor for atherosclerotic CVD and calcific aortic valvular disease. Lp(a) continues to be studied, with emerging insights into the epidemiology of CVD with respect to Lp(a), pathogenic mechanisms of Lp(a) and strategies to mitigate disease. There have been novel insights into genetic polymorphisms of the LPA gene, interactions between concomitant risk factors and Lp(a) based on real-world data, and metabolic pathway targets for Lp(a) reduction. This review highlights these recent advances in our understanding of Lp(a) and discusses management strategies as recommended by cardiovascular professional societies, emerging therapies for lowering Lp(a), and future directions in targeting Lp(a) to reduce CVD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisCardiovascular DiseasesAtherosclerosisHumansLipoprotein(a)Aortic ValveRisk Factors

Stichwörter der Autor:innen

AtherosclerosisCalcific aortic stenosisCoronary artery diseaseDyslipidemiaGeneticsLipoprotein(a)PathophysiologyRisk factors

Substanzen

Lipoprotein(a)

Autor:innen und Institutionen

  • Cardiology Division, NYU Langone Health and NYU School of Medicine, New York, NY, United States of America. Electronic address: chayakrit.krittanawong@va.gov.
  • Division of Cardiology, Scripps Clinic, La Jolla, CA, United States of America.
  • Faculty of Health Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
  • Division of Cardiology, Duke Heart Center, Duke University, 2301 Erwin RD, Durham, NC, United States of America.
  • John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, United States of America.
  • Section on Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States of America; Center for Prevention of Cardiovascular Disease, Medical Center Bouleva…

Zitieren

APA

Krittanawong, C., Maitra, N. S., El-Sherbini, A. H., Shah, N., Lavie, C. J., Shapiro, M. D., & Virani, S. S. (2023). Lipoprotein(a) in clinical practice: A guide for the clinician. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2023.07.006

Vancouver

Krittanawong C, Maitra NS, El-Sherbini AH, Shah N, Lavie CJ, Shapiro MD, et al. Lipoprotein(a) in clinical practice: A guide for the clinician. Progress in Cardiovascular Diseases. 2023. doi:10.1016/j.pcad.2023.07.006

BibTeX
@article{Krittanawong2023,
  author = {Krittanawong, Chayakrit and Maitra, Neil Sagar and El-Sherbini, Adham H and Shah, Nishant and Lavie, Carl J and Shapiro, Michael D and Virani, Salim S},
  title = {Lipoprotein(a) in clinical practice: A guide for the clinician},
  journal = {Progress in Cardiovascular Diseases},
  year = {2023},
  doi = {10.1016/j.pcad.2023.07.006}
}
Kostenlos starten →